

Tudor Eliade Ciuleanu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7640160/publications.pdf>

Version: 2024-02-01

38
papers

14,528
citations

331670

21
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

10442
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 123-132.	27.0	5,267
2	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa). <i>Lancet</i> , 2009, 374, 1251-1260.	10.7	1,051
3	Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , 2019, 394, 1929-1939.	13.7	1,274
4	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , 2010, 11, 521-529.	10.7	1,158
5	Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. <i>Lancet</i> , 2009, 374, 1432-1440.	13.7	1,062
6	Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5034-5042.	1.6	701
7	The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. <i>International Journal of Cancer</i> , 2010, 127, 2209-2221.	5.1	464
8	Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1345-1353.	1.1	416
9	Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , 2012, 13, 300-308.	10.7	360
10	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01). <i>Journal of Clinical Oncology</i> , 2010, 28, 467-474.	10.7	318
11	Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. <i>Lung Cancer</i> , 2006, 52, 155-163.	2.0	304
12	A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244) in patients who have failed first-line gemcitabine therapy. <i>Investigational New Drugs</i> , 2012, 30, 1216-1223.	2.6	196
13	Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4787-4792.	1.6	176
14	Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3640-3647.	1.6	166
15	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. <i>European Journal of Cancer</i> , 2020, 127, 160-172.	2.8	112
16	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 545-555.	1.1	87
17	XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2009, 4, 736-740.	1.1	81
18	A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. <i>BMC Cancer</i> , 2017, 17, 137.	2.6	47

#	ARTICLE	IF	CITATIONS
19	Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. <i>European Journal of Cancer</i> , 2017, 78, 61-69.	2.8	25
20	Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. <i>British Journal of Cancer</i> , 2020, 122, 1461-1466.	6.4	24
21	Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non-Small-Cell Lung Cancer: A Lead-In Study. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1406-1416.	1.1	22
22	A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. <i>Lung Cancer</i> , 2012, 78, 63-69.	2.0	22
23	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. <i>Translational Lung Cancer Research</i> , 2015, 4, 465-74.	2.8	21
24	Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 130-138.e2.	2.6	19
25	Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 233-241.	2.3	18
26	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 599-608.	2.3	18
27	Profiling immunohistochemical expression of NOTCH1, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 603-614.	3.3	15
28	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , 2018, 3, e000347.	4.5	15
29	Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 159-174.	1.8	14
30	Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. <i>European Urology</i> , 2022, 82, 283-292.	1.9	14
31	Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. <i>International Journal of Cancer</i> , 2018, 142, 66-80.	5.1	13
32	Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment. <i>Journal of Medical Ultrasonics (2001)</i> , 2015, 42, 271-276.	1.3	10
33	Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 104, 45-51.	2.0	9
34	A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naïve patients with stages III and IV non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2007, 57, 168-174.	2.0	7
35	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5275-5291.	2.0	5
36	Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4314.	2.6	5

#	ARTICLE	IF	CITATIONS
37	Second-line erlotinib for non-small-cell lung cancer – Authors' reply. Lancet Oncology, The, 2012, 13, e142.	10.7	0
38	Development and Evaluation of a Software-based Clinical Pharmacography System. Studies in Informatics and Control, 2015, 24, .	1.2	0